Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2016

View Archived Issues

mAbxience and UCAB to lead palivizumab biosimilar project for RSV

Umecrine Cognition raises funds to support clinical development of GR-3027

ANI to acquire Inderal LA assets from Cranford Pharmaceuticals

FDA grants orphan drug designation for PNT-2258 for the treatment of DLBCL

Sylentis reports positive phase II results for SYL-1001

DREAM silencing associated with early neuroprotection in Huntington's disease

Ritter Pharmaceuticals initiates phase IIb/III study of RP-G28

First patients dosed in Quark Pharmaceuticals' pivotal studies

Inovio Pharmaceuticals acquires Bioject's needle-free injection technology

Tesaro submits NDA for intravenous rolapitant

Imbruvica available in U.S. as first-line treatment for CLL

Japanese scientists patent E-NPP 2 inhibitors

UCL Business discloses cyclophilin D inhibitors

ViveBio and Butantan Institute collaborate to evaluate ViveST technology in dengue trial

Northwestern University reports development of APOBEC-3G expression enhancers

Taisho Pharmaceutical presents antibacterial agents

FDA accepts Aeglea's IND for AEB-1102 for hematological malignancies

Eli Lilly develops novel EP4 receptor antagonists

Celator's phase III trial of Vyxeos for high-risk AML meets primary endpoint

Epidiolex treatment leads to significant reduction in convulsive seizures in phase III pivotal trial

FDA grants priority review to atezolizumab BLA for advanced bladder cancer

Navidea Biopharmaceuticals and Platinum sign agreement reaffirming loan obligations

miR-26b may be useful as a prognostic biomarker in advanced breast cancer

BioInvent and Oncurious partner with research consortium for phase I/IIa study of TB-403

Takeda and Frazier Healthcare launch Outpost Medicine

Lower TSPO expression may be a marker of poor prognosis in ACC

Dacomitinib evaluated in advanced or metastatic PSCC chemonaive patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...